[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,350,864
  • Shares Outstanding, K 23,056
  • Annual Sales, $ 958,400 K
  • Annual Income, $ -288,280 K
  • EBIT $ -314 M
  • EBITDA $ -307 M
  • 60-Month Beta -1.05
  • Price/Sales 13.31
  • Price/Cash Flow N/A
  • Price/Book 23.47

Options Overview Details

View History
  • Implied Volatility 59.69% (-1.04%)
  • Historical Volatility 34.46%
  • IV Percentile 78%
  • IV Rank 61.93%
  • IV High 73.99% on 11/03/25
  • IV Low 36.43% on 05/06/26
  • Expected Move (DTE 31) 29.75 (5.47%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 23
  • Volume Avg (30-Day) 302
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 10,474
  • Open Int (30-Day) 17,045
  • Expected Range 513.86 to 573.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.66
  • Number of Estimates 5
  • High Estimate $-2.03
  • Low Estimate $-3.19
  • Prior Year $-1.90
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
500.80 +8.41%
on 06/22/26
569.44 -4.65%
on 07/09/26
+37.19 (+7.35%)
since 06/18/26
3-Month
445.20 +21.95%
on 06/03/26
569.44 -4.65%
on 07/09/26
+15.25 (+2.89%)
since 04/21/26
52-Week
286.44 +89.55%
on 07/30/25
615.00 -11.72%
on 12/24/25
+212.00 (+64.06%)
since 07/21/25

Most Recent Stories

More News
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30,...

MDGL : 543.40 (+1.44%)
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering...

MDGL : 543.40 (+1.44%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 543.40 (+1.44%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 543.40 (+1.44%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 543.40 (+1.44%)
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47 th Annual Global Goldman Sachs Health Care...

MDGL : 543.40 (+1.44%)
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Growing body of clinical and real-world evidence supports the role of Rezdiffra ® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles...

MDGL : 543.40 (+1.44%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 543.40 (+1.44%)
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year...

MDGL : 543.40 (+1.44%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 543.40 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 571.54
2nd Resistance Point 563.30
1st Resistance Point 549.49
Last Price 543.40
1st Support Level 527.44
2nd Support Level 519.20
3rd Support Level 505.39

See More

52-Week High 615.00
Last Price 543.40
Fibonacci 61.8% 489.49
Fibonacci 50% 450.72
Fibonacci 38.2% 411.95
52-Week Low 286.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.